[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]

Turkish Journal of Cancer
1993, Volume 23, Number 3, Page(s) 126-133
[ Summary ] [ Similar Articles ] [ Mail to Editor ]
Single-agent and combination chemotherapy in small cell lung cancer
ÖZGÜR ÖZYILKAN1, GÜLTEN TEKUZMAN1, AYŞE KARS1, İBRAHİM BARIŞTA1, EŞMEN BALTALI1, ŞEVKET RUACAN2, YAVUZ ÖZIŞIK1, EMİN KANSU1, DİNÇER FIRAT1
Departments of 1Medical Oncology and 1Pathology, Hacettepe University, Institute of Oncology, Ankara-Turkey
Keywords: Small cell lung cancer, chemotherapy
Summary
This is a retrospective analysis of 64 patients with small cell lung cancer who were treated with five different chemotherapy regimens from 1979 to 1990. Twenty patients received single agent regimens consisting of etoposide (E) or cyclophosphamide (C), and the median survivals were 10 months (range 2 to 15) and 4 months (range 2 to 9), respectively. Twenty-six patients were treated with a combination of adriamycin, cyclophosphamide, and etoposide (ACE), and the median survival was 5 months (range 2 to 33). Nine patients were treated with a combination of cyclophoshamide, adriamycin, and vincristine. The median survival of these patients was 3 months (range 2 to 12). Nine patients received a combination of cyclophosphamide, epirubicin, and etoposide alternating with a combination of cisplatin and etoposide (CBE-PE). The median survival was 3 months (range 2 to 18). The differences between the groups were statistically insignificant (p>0.05).
  • Top
  • Summary
  • [ Top ] [ Summary ] [ Similar Articles ] [ Mail to Editor ]
    [ Main Page | Editorial Board | About | Instructions ]
    [ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]